tradingkey.logo

tradingkey.logo
怜玢


Connect Biopharma Holdings Ltd

CNTB
りォッチリストに远加
0.677USD
+0.012+1.80%
終倀 11-13 16:00ET
37.72M時䟡総額
損倱額盎近12ヶ月PER

Connect Biopharma Holdings Ltdに぀いお 䌁業名

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Connect Biopharma Holdings Ltd プロフィヌル


䌁業コヌドCNTB
䌚瀟名Connect Biopharma Holdings Ltd
䞊堎日Mar 19, 2021
最高経営責任者「CEO」Quart (Barry D)
埓業員数62
蚌刞皮類Ordinary Share
決算期末Mar 19
本瀟所圚地3580 Carmel Mountain Road, Suite 200
郜垂SAN DIEGO
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号92130
電話番号18587271040
りェブサむトhttps://www.connectbiopharm.com
䌁業コヌドCNTB
䞊堎日Mar 19, 2021
最高経営責任者「CEO」Quart (Barry D)

Connect Biopharma Holdings Ltdの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
91.55K
+5.46%
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Senior Vice President - Finance
Senior Vice President - Finance
45.19K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
20.76K
+43.27%
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--
Mr. David L. Szekeres
Mr. David L. Szekeres
President
President
--
--
Mr. James Z. Huang
Mr. James Z. Huang
Independent Director
Independent Director
--
--
Mr. James A. (Jim) Schoeneck
Mr. James A. (Jim) Schoeneck
Independent Director
Independent Director
--
--
Ms. Kimberly J. Manhard
Ms. Kimberly J. Manhard
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
91.55K
+5.46%
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Senior Vice President - Finance
Senior Vice President - Finance
45.19K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
20.76K
+43.27%
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--

よくある質問

Connect Biopharma Holdings Ltdの䞊䜍5名の株䞻は誰ですか


Connect Biopharma Holdings Ltdの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Barry D. Quart, Pharm.D.

Connect Biopharma Holdings LtdCNTBの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Connect Biopharma Holdings Ltdの株匏を保有しおいる機関は51瀟あり、保有株匏の総垂堎䟡倀は玄29.94Mで、党䜓の52.97%を占めおいたす。2025Q4ず比范しお、機関の持ち株は8109973.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。